Corrigendum to "Affinity labeling of the proteasome by a belactosin A derived inhibitor" [Bioorg. Med. Chem. Lett. 18 (2008) 5668] (DOI:10.1016/j.bmcl.2008.08.073);Affinity labeling of the proteasome by a belactosin A derived inhibitor

Bioorganic and Medicinal Chemistry Letters

Volumn 18, Issue 20, 2008, Pages 5668-5671

  Hasegawa, Makoto ^a   Kinoshita, Kazuhiro ^a   Nishimura, Chika ^a   Matsumura, Umechiyo ^a   Shionyu, Masashi ^a   Ikeda, Shun ichi ^b   Mizukami, Tamio ^a  

^a NAGAHAMA INSTITUTE OF BIO SCIENCE AND TECHNOLOGY   (Japan)

^b KYOWA HAKKO KOGYO CO LTD   (Japan)

Author keywords

Affinity label; Anti cancer drug; Protease inhibitor; Proteasome

Indexed keywords

BELACTOSIN A; BELACTOSIN A DERIVED INHIBITOR; DANSYL KF 33955; PROTEASOME; UNCLASSIFIED DRUG;

ARTICLE; CATALYSIS; CELL MEMBRANE PERMEABILITY; DRUG POTENCY; HYDROPHOBICITY; IN VIVO STUDY; NONHUMAN; PROTEIN DEGRADATION; STREPTOMYCES;

STREPTOMYCES;

EID: 53449087088     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2008.08.117     Document Type: Erratum

References (18)

1. Eytan E., Ganoth D., Armon T., and Hershko A. Proc. Natl. Acad. Sci. U.S.A. 86 (1989) 7751
2. Baumeister W., Walz J., Zuhl F., and Seemuller E. Cell 92 (1998) 367
3. Kisselev A.F., and Goldberg A.L. Chem. Biol. 8 (2001) 739
4. Asai A., Hasegawa A., Ochiai K., Yamashita Y., and Mizukami T. J. Antibiot. (Tokyo) 53 (2000) 81
5. Asai A., Tsujita T., Sharma S.V., Yamashita Y., Akinaga S., Funakoshi M., Kobayashi H., and Mizukami T. Biochem. Pharmacol. 67 (2004) 227
6. Groll M., Larionov O.V., Huber R., and de Meijere A. Proc. Natl. Acad. Sci. U.S.A. 21 (2006) 4576
7. ++H): 806.370 (calcd 806.372).
8. Kisselev A.F., and Goldberg A.L. Methods Enzymol. 398 (2005) 364
9. 50 values.
10. 2. The viability of HeLa cells was tested using an MTT assay after incubation with inhibitors added at various concentrations for 48 h. Treatment with (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl) tetrazolium bromide (MTT) was performed according to the manufacturer's protocol. Absorbance at 570 nm was measured using a plate reader.
11. Berkers C.R., Verdoes M., Lichtman E., Fiebiger E., Kessler B.M., Anderson K.C., Ploegh H.L., Ovaa H., and Galardy P.J. Nat. Methods 2 (2005) 357
12. HeLa cells were mixed with various concentrations of clasto-lactacystin β-lactone and MG132 and incubated for 1 h at 37 °C in serum-free medium. Next, they were mixed with 1.0 μM dansyl-KF33955 and incubated for another hour. To stop the assay, the cells were collected by centrifugation (15,000g, 5 min), treated with denaturing buffer (60 mM Tris-HCl pH 8.8, 5 M urea, 1 M thiourea, 5 mM EDTA, 1% CHAPS, 1% Triton X-100) at 4 °C, and lysed by sonication. The samples were separated by SDS-PAGE and protein bands on the gel were visualized by SYPRO-Red staining (Invitrogen Co.). Images were acquired using a FLA3000 laser scanner (Fuji Photo Film Co., Ltd., Tokyo, Japan). Following transfer onto a PVDF membrane, immunodetection using an anti-dansyl monoclonal antibody (Santa Cruz Biotechnology) was performed. HRP-conjugated anti-rabbit IgG (MBL) was used as the secondary antibody. Signals were visualized using an ECL Plus detection kit (Amersham Biosciences) and an LAS-1000 Plus image analyzer (Fuji Photo Film Co., Ltd.).
13. 2, 0.5 mM EDTA, 1 mM dithiothreitol, and 1 mM ATP). The cells were permeabilized by the addition of 0.025% digitonin and incubation on ice for 5 min. The cytosol was "squeeze out" by centrifugation for 15 min at 15,000g. The supernatants were used for the next experiments.
14. 10
15. Köhler A., Cascio P., Leggett D.S., Woo K.M., Goldberg A.L., and Finley D. Mol. Cell 7 (2001) 1143
16. Smith D.M., Chang S.C., Park S., Finley D., Cheng Y., and Goldberg A.L. Mol. Cell 27 (2007) 731
17. Groll M., Bajorek M., Köhler A., Moroder L., Rubin D.M., Huber R., Glickman M.H., and Finley D. Nat. Struct. Biol. 7 (2000) 1062
18. Unno M., Mizushima T., Morimoto Y., Tomisugi Y., Tanaka K., Yasuoka N., and Tsukihara T. Structure 10 (2002) 609